Cardiologists make history, treat world’s first patient with new interventional device for chest pain
VahatiCor, a new medical device company associated with California-based T45 Labs, announced that the very first patient has been successfully treated with its A-Flux Reducer System for chest pain.
The A-Flux Reducer System is intended to be a new therapy option for “no-option” chest pain patients who see no benefits from other available interventional or surgical treatments. Interventional cardiologists implant the self-expandable device percutaneously into the patient’s coronary, where it increases blood flow in a way that provides more oxygen to the heart and relieves symptoms. It was designed to “conform seamlessly” to any patient’s anatomy, according to VahatiCor, and it can be repositioned or retrieved as necessary.
The first successful implant of this new device was performed on an angina patient from Canada by interventional cardiologists Jean-Michel Paradis, MD, and Can Manh Nguyen, MD, at the Quebec Heart and Lung Institute.
VahatiCor's A-Flux Reducer System is intended to be a new therapy option for “no-option” chest pain patients who see no benefits from other available interventional or surgical treatments.
“We have many interventional or surgical revascularization options for patients with advanced large coronary artery disease,” Paradis said in a statement.. “However, a significant proportion still suffer from angina. The A-Flux Reducer could help to fill that therapeutic void. It was an honor to perform the first-in- human implant and the patient is doing great.”
“The A-Flux Reducer System is a promising intervention with the potential to provide a predictable and low-risk treatment for a growing population of patients with angina symptoms that do not respond well to medicines and lifestyle changes,” Nguyen added.
In the same statement, Howard Edelman, CEO of VahatiCor, highlighted the new device’s potential to treat microvascular angina.
“We are encouraged by the positive early clinical experience with A-Flux and are moving forward quickly to a larger study that will support the availability of the device for more patients,” he said.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.